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Abstract 
Background: Inattention to symptoms of mental disorders and substance abuse in patients with HIV/AIDS 
and other at-risk groups, may lead to irreversible damages. The purpose of this study was to compare the 
psychopathological dimensions in substance abusers with and without HIV/AIDS and healthy matched 
groups. 
Methods: In a cross-sectional and analytical study, selected samples (by available, consecutive, and objective 
methods) were 43 HIV-positive substance abusers, 49 HIV negative substance abusers under methadone 
maintenance therapy (MMT) in the counseling clinic of Behavioral Diseases and Addiction Abandonment, 
and 45 ordinary individuals. All of them were evaluated by matched confounding variables via Symptom 
Checklist-90-Revised (SCL-90-R). 
Findings: Results indicated a significant difference between these groups in the Global Severity Index (GSI), 
Positive Symptom Distress Index (PSDI), and Positive Symptom Total (PST) (P < 0.001). Two by two the 
comparison of the three groups from psychopathological dimensions revealed that substance abusers with 
HIV/AIDS persistently suffer more mental problems in all dimensions compared with healthy individuals  
(P < 0.05). In addition, in comparison with HIV negative substance abusers, they also suffer more mental 
problems in other dimensions, including somatization, interpersonal sensitivity, depression, anxiety, phobia, 
and psychoticism (P < 0.05). Yet, the difference in paranoid ideation, hostility, and obsessive-compulsive 
cases was insignificant. Two by two, the comparison between healthy individuals and substance abusers 
without HIV/AIDS showed higher levels of depression and psychoticism in substance abusers (P < 0.05), but 
no difference in other dimensions. 
Conclusion: Comorbidity of substance abuse and HIV diagnosis intensify mental disorder symptoms. 
Moreover, lack of prevention and implementation of appropriate psychological and psychiatric interventions 
after substance abuse and HIV lead to extended establishment of mental disorder symptoms. 
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Introduction 
Despite the remarkable advances in medicine, 
AIDS is still killing millions of people every day 
and HIV is increasingly spreading worldwide. 
This biopsychosocial phenomenon rapidly affects 
social structures and individual entity.1 HIV and 
AIDS should not be considered as a simple health 
problem, since social and economic complications 
of the disease has such a wide range of 
dimensions that make it difficult to compare with 
other present epidemic diseases. 
AIDS is beyond just clinical manifestations 
(e.g. skin infections, tuberculosis, bacterial 
pneumonia, thrombophlebitis, hepatitis B and C, 
and etcetera), which co-occur with the 
progression of HIV infection and damage to 
cellular immune system.2 Evidences have shown 
that these patients are affected by a wide range of 
mental disorders, and nearly 20% to 59% of HIV-
infected people suffer from one or more mental 
disorders, which is 2 or 3 times general 
population.3-9 
In this regard, substance use disorder is the 
most common comorbid in mental disorders of 
HIV-infected patients.5,10 Prior researches have 
associated substance use, especially in the form of 
injection, with some HIV epidemics around the 
world. The prevalence and frequency of medical 
and mental disorders are higher in HIV-infected 
substance users. Consequently, due to the large 
number and wide range of these dual disorders, 
diagnosis and treatment in these patients become 
more complicated, and result in a large number of 
challenges for a thorough care.10 For instance, in 
some studies, the rate of substance use disorder 
was 70% or more and the it prevalence 
considering age and gender may be at least 3 
times higher than expected.11,12 Moreover, some 
studies revealed that the onset of mood and 
substance use disorders was prior to the possible 
time of acquiring HIV infection.13,14 Moreover, 
mental disorders in HIV-infected individuals is 
accompanied with a drop in quality of life score 
and reduction of adherence or compliance to 
antiretroviral therapy.15-18 
The influence of HIV on the young population 
of Iran is becoming obvious, especially during 
recent years. According to the latest report by the 
Ministry of Health and Medical Education (Iran), 
the number of HIV-infected people is 23,125 
(22/June/2011). 4311 people diagnosed with 
AIDS have died, 46.5% were between 25-34 years 
of age.19 Therefore, like other countries, HIV 
infection involves the young population of Iran in 
respect to their reproduction and economical 
activities, and social communication. 
However, without exact the diagnosis and 
efficient treatment for mental disorders one 
should not expect a reduction in the disastrous 
outcome of HIV/AIDS and its transmission to 
other people or substance users. Promoting public 
awareness leaning on local researches may help 
therapists, who first visit these patients, to offer 
successful care. Besides, there are a limited 
number of data on recognition of mental 
disorders in substance users with and without 
HIV/AIDS and their healthy matched group for 
quick reference and treatment. Thus, the main 
goal of this research is to identify the difference 
between the 3 groups in respect to the diverse 
dimensions of psychopathology. Therefore, 
understanding psychopathology in at-risk groups 
may show the necessity for revealing fundamental 
data in this regard, prioritizing the symptoms of 
mental disorder, and precise program planning to 
offer health and mental services. 
Methods 
Research plan 
This was a cross-sectional study. The medical 
ethics and the plan were approved by the Research 
Council of Guilan University of Medical Sciences 
(GUMS), Iran [NO. P/3/132/10617 approved on 
8/June/2010]. The subjects were the following 
groups: A) confirmed HIV-infected substance users 
under highly active antiretroviral therapy 
(HAART) B) substance users without HIV/AIDS 
C) healthy matched group for both A and B groups 
with no special morbidity. All participants of 
group A were under supervision of the Research 
Council of GUMS in 2010 and had record files. 
Furthermore, group B with substance abuse history 
referred to the same behavioral Disease Counseling 
Clinic, a Drop in Center (DIC), and two other drug 
abandonment centers in Rasht, Iran. Group C 
consisted of healthy individuals who were relatives 
of patients in A and B groups and the staff who 
worked with these patients.  
 
Participants  
The sample size was 43 individuals in each group  
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and 129 subjects in total for 3 groups with 99% 
confidence interval (CI) and considering 95% 
statistical power based on sample size 
determination table for variance analysis by 
Bratcher et al.20 In the sampling procedure, from 
June to September 2010, first substance users with 
HIV/AIDS were included in the project by 
convenience sampling method, and then, 
substance users without HIV/AIDS by 
consecutive method. All patients were referred 
the medical centers due to a history of risky 
behavior (e.g. drug injection, sharing syringe, 
unsafe sexual behavior, and etcetera), or for a free 
voluntary counseling and testing (VCT) and 
Methadone Maintenance Therapy (MMT). Shortly 
before starting, and during the project, damage 
reduction and care program (pre-test counseling, 
giving condom and syringe, and etcetera) were 
performed. Before HIV diagnostic test, they were 
assured that the test is safe and free. Blood 
samples (2cc) were sent to Guilan Blood 
Transfusion Organization for enzyme-linked 
immunosorbent assay (ELIZA) by Bio-Rad kit 
with confirmatory western blot assay by 
Innogenetic kit. Finally, those who were HIV-
positive were tested for CD4 count of T-helper 
lymphocytes in GUMS. The number of CD4 is a 
good index to determine the severity of disease 
progression and plays a key role in cellular 
defense system; the less the count, the more 
vulnerable the body to other infections.21 The 
healthy group were selected by purposive 
sampling method out of patients' acquaintances, 
staff, and service workers of hygiene and drug 
abandonment centers. The reason for using non-
random sampling method in substance abusers 
without HIV/AIDS and the healthy group was to 
match HIV/AIDS substance abusers more 
accurately according to age, gender, marital status, 
education level, and place of living (urban, rural). 
The inclusion criteria for the HIV/AIDS group 
were two positive ELISA serum tests and a 
positive western blot assay plus AIDS symptoms 
determined and recorded in their file by a 
specialist and other experts. In the non-
HIV/AIDS substance abusers group, their HIV 
tests were negative and were added to their 
record file. For the healthy matched group "no 
history of substance abuse" was considered as a 
criterion. Moreover, inclusion criteria for all 3 
groups were being above 18 years of age, 
acceptable understanding of the procedure, and 
no acute psychiatric disease (e.g. schizophrenia) 
and developmental-neuronal disorders (e.g. 
retardation, brain damage, dementia, and other 
cognitive disorders). A written consent form was 
obtained from each participant. The exclusion 
criteria were identified by examining and 
interviewing patients, and reviewing their files by 
a doctor and specialist in behavioral diseases in 
the center.  
 
Measures 
Symptom checklist–90-Revised (SCL-90-R): This 
test is a powerful self-report tool for 
psychopathological assessment specifically 
intended for those physical and psychological 
disorders recently experienced by respondents. 
The 90 items of this test describe symptoms most 
experienced and reported by medical and 
psychiatric patients. The first version of this test 
was introduced by Derogatis et al. in 1973, 
followed by a revision based on clinical 
experiences and psychometric analysis that 
created the final version.22,23 The 90 items of this 
test include 9 dimensions; somatization, 
obsessive-compulsive, interpersonal sensitivity, 
depression, anxiety, hostility, phobia, paranoid 
ideation, and psychoticism. All given answers to 
the items are placed in a 5-degree scale (0 = none, 
1 = a little, 2 = to some extent, 3 = very much, and 
4 = extremely).24 It takes about 10-15 minutes to 
answer this questionnaire.  
Grading and interpretation of the results are 
done based on the Global Severity Index (GSI), 
Positive Symptom Distress Index (PSDI), and 
Positive symptom Total (PST).24 Derogatis has 
utilized the internal reliability and retest 
reliability to assess the reliability of the 9 
dimensions of this test. Internal reliability of 
SCL-90-R for 9 dimensions was satisfying and the 
most internal consistency was about depression 
with 0.90 and the least was about psychoticism 
with 0.77. Retest reliability varied between 0.78 to 
0.90.25 Similarly, Bagheri Yazdi et al. reported a 
0.97 reliability coefficient and 0.94, 0.98, and 0.96 
for sensitivity, specificity, and efficiency, 
respectively.26 They suggested SCL-90-R to be 
used as a diagnostic screening tool in 
epidemiologic studies of mental disorders. In the 
current project, based on a survey by Noorbala 
et al., who calculated cut-off point of SCL-90-R 
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test to be 0.7 in Iran based on GSI coefficient, 
individuals with GSI > 0.7 are considered as 
having mental disorder.27 Previously, SCL-90-R 
was successfully applied in researches related to 
mental symptoms assessment and in patients with 
HIV/AIDS.9,28-31 Mohseni and Hedayati-
Moghadam et al. used the same cut-off point (0.7) 
to determine the extent of mental disorders in 
HIV/AIDS infected patients in Iran.9,28 
Furthermore, a researcher-made questionnaire 
was used to record demographic characteristics 
for all 3 groups, and some clinical information 
such as present status of drug use, HIV infection 
status of spouse, history of syringe addiction, and 
number of CD4 lymphocytes in substance abusers 
with and without HIV/AIDS.  
 
Project procedure 
The interviews were performed by two MA 
psychologists; after getting to know the 
participants in the sampling setting they 
explained the general aim of the research to them. 
Considering the low literacy of some subjects, all 
questions were read and their verbal responses 
registered to equalize the test completion method. 
They were also assured that all information 
would be confidential and published as the total 
result. They were also informed that they could 
quit the study whenever they decided and it 
would not negatively affect the diagnostic and 
treatment procedure. 
Statistical Analysis 
After scoring, data of the 3 subject groups were 
analyzed by SPSS 16.0 statistical package 
(SPSS Inc., Chicago, IL., USA) using descriptive 
statistic indices, Student’s independent t-test for 
two-group comparisons, χ2 to compare the 
observed frequency of suspected cases for mental 
disorders, and one way Analysis Of Variance 
(ANOVA) to exhibit the main effects of group 
membership (substance abusers with HIV/AIDS, 
substance abusers without HIV/AIDS, and their 
matched group). Gabriel post-hoc test was also 
utilized to determine the significant difference 
between the mean of the 3 groups' scores. 
Results 
Out of the 150 distributed questionnaires, data of 
43 HIV/AIDS substance abusers, 49 non-
HIV/AIDS substance abusers, and 45 healthy 
matched individuals were collected. As is shown 
in table 1, the results of ANOVA and χ2 show no 
significant difference between likely confounding 
variables (P > 0.05). 
The mean of CD4 lymphocyte count in 
confirmed HIV+ substance abusers was  
377.74 ± 202 (from 36 to 830). Muma et al. 
indicated lymphocyte count (in 1 mm2 of blood 
sample) < 200 CD4 as inclusion criterion for AIDS 
phase.21 In our study, 7 patients (16.3%) had 
entered this phase. Mean of positive HIV period 
was 20 ± 24 months based on medical records. 37  
  
Table 1. Demographic characteristics of participants based on matched variables (n = 137) 
Quantitative matched variables* HIV positive HIV negative Healthy matched P 
(n = 43) (n = 49) (n = 45) 
Age (year) 33.81 ± 7.76 34.96 ± 9.80 32.18 ± 10.54 NS 
Education (years) 8.04 ± 2.92 7.40 ± 1.88 9.93 ± 2.34 NS 
Qualitative matched variables† n (%) n (%) n (%)  
Gender 
NS Male 38 (88.3) 44 (89.8) 36 (80.0) 
Female 5 (11.7) 5 (10.2) 9 (20.0) 
Marital status 
NS 
Single 20 (46.5) 27 (55.1) 20 (44.4) 
Married 17 (39.5) 18 (36.7) 25 (55.6) 
Divorced 4 (9.3) 3 (6.1) 0 (0.0) 
Widow 2 (4.7) 1 (2.1) 0 (0.0) 
Living place 
NS Rural 37 (86.1) 41 (83.7) 42 (93.4) 
Urban 6 (13.9) 8 (16.3) 3 (6.6) 
* ANOVA test; † χ2 test; NS: Not significant 
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(86.0%) of the 43 HIV/AIDS substance abusers were 
under MMT and 34 (79.1%) reported drug injection 
history. In addition, 46 (93.9%) of the 49 non- 
HIV/AIDS substance abusers were under MMT, 
and 29 (59.2%) reported drug injection history. The 
results of χ2 revealed that HIV/AIDS substance 
abusers and non- HIV/AIDS substance abusers 
were significantly different in drug injection history 
(χ2 = 4.20, df = 1, P = 0.041). HIV/AIDS substance 
abusers had significantly higher rate of drug 
injection history (79.1% vs. 59.2 %).  
The results of this study showed that there is no 
significant difference in Methadone consumption 
period between HIV and non-HIV substance 
abusers (t = 1.09, df = 90, P = 0.280). However, 
there is a significant difference in the results of 
independent t-test about imprisonment period. In 
other words, HIV/AIDS infected substance 
abusers are on average imprisoned twice more 
than the other group (t = 2.57, df = 90, P = 0.012). 
As shown in table 2, in comparison analysis of 
mental disorder prevalence in studied groups 
based on cut-off point, general symptom index 
(GSI) has been considered as 0.7. 88.4% of 
HIV/AIDS substance abusers, 75.5% of non-
HIV/AIDS substance abusers, and 53.0% of their 
healthy matched group that showed mental 
disorder symptoms are significant based on χ2  
(χ2 = 13.87, df = 2, P < 0.001). 
Table 3 shows the number distribution  
(Mean ± SD) and results of ANOVA of subscales 
of the SCL-90-R test, representing diverse mental 
aspects of the psychopathology of HIV/AIDS and 
non-HIV/AIDS groups, and their healthy 
matched group. 
As seen in table 3, there is a significant 
difference between these 3 groups in all 
psychopathological dimensions (i.e. the ratio of 
calculated F by free grades is 2 and 134) and all 
subscales of SCL-90-R test (P < 0.05). Table 4 also 
presents the results of two-by-two mean 
comparison of groups using Gabriel post-hoc test, 
the power of which is good particularly in 
discriminating unequal groups with different 
sample sizes.32 
Gabriel post-hoc test showed that HIV/AIDS 
substance abusers report significantly more 
symptoms and show a more acute mental status in 
all dimensions compared to their healthy matched 
group. This is also true in all psychopathological 
dimensions, except hostility and paranoid ideation, 
compared to non-HIV/AIDS substance abusers. 
There was also a significant difference in depression, 
anxiety, psychoticism, GSI, and PSDI between 
substance abusers without HIV/AIDS and the 
healthy matched group. 
 
Table 2. Mental disorders in the 3 groups of substance abusers with and without HIV/AIDS and healthy matched group 
Mental disorder status 
Groups 
Yes No χ2 P n (%) n (%) 
HIV positive (n = 43) 38 (88.4) 5 (11.6) 
13.87 < 0.001 HIV negative (n = 49) 37 (75.5) 37 (24.5) 
Healthy matched (n = 45) 24 (53.3) 24 (46.7) 
 
Table 3. Results of Analysis of Variance (ANOVA) of psychopathology dimensions in the 3 groups 
 Groups  
 
SCL-90-R dimensions 
HIV positive  HIV negative Healthy matched F 
(134,2) 
P (n = 43) (n = 49) (n = 45) 
Mean ± SD Mean ± SD Mean ± SD 
Somatization 17.76 ± 11.11 10.65 ± 8.36 9.18 ± 5.19 12.79 < 0.001 
Obsessive-compulsive 16.32 ± 8.55 12.57 ± 7.57 9.22 ± 6.31 9.82 < 0.001 
Interpersonal sensitivity 16.91 ± 8.22 11.94 ± 7.67 8.58 ± 5.42 14.83 < 0.001 
Depression 25.23 ± 12.70 16.92 ± 10.31 10.98 ± 7.41 21.09 < 0.001 
Anxiety 15.18 ± 9.06 10.33 ± 7.02 7.29 ± 5.60 12.97 < 0.001 
Hostility 7.74 ± 6.11 5.94 ± 4.35 4.98 ± 4.17 3.57 < 0.031 
Phobia 7.77 ± 5.63 4.69 ± 4.14 3.11 ± 2.81 13.16 < 0.001 
Paranoid ideation 11.72 ± 5.43 9.28 ± 5.62 7.04 ± 4.93 8.41 < 0.001 
Psychoticism 15.56 ± 8.42 10.71 ± 6.72 4.95 ± 5.74 25.21 < 0.001 
Global Severity Index (GSI) 1.62 ± 0.76 1.13 ± 0.61 0.81 ± 0.47 19.12 < 0.001 
Positive Symptom Total (PST) 58.09 ± 19.10 46.69 ± 17.61 41.58 ± 18.25 9.37 < 0.001 
Positive Symptom Distress Index (PSDI) 2.42 ± 0.59 2.08 ± 0.50 1.71 ± 0.43 21.20 < 0.001 
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Table 4. Results of two-by-two mean comparison of groups by Gabriel post-hoc test in different dimensions of 
psychopathology 
Groups 
Variables SCL-90-R dimensions 
Mean difference Mean A B 
Somatization 
A: HIV positive - - 17.76 
B: HIV negative 7.11*** - 10.65 
C: Healthy matched 8.59*** 1.47 9.18 
     
Obsessive-compulsive 
A: HIV positive - - 16.32 
B: HIV negative 3.75* - 12.57 
C: Healthy matched 7.10*** 3.35 9.22 
     
Interpersonal sensitivity 
A: HIV positive - - 16.91 
B: HIV negative 4.97* - 11.94 
C: Healthy matched 8.33*** 3.36 8.58 
     
Depression 
A: HIV positive - - 25.23 
B: HIV negative 8.31** - 16.92 
C: Healthy matched 14.25*** 5.94* 10.98 
     
Anxiety 
A: HIV positive - - 15.18 
B: HIV negative 4.86** - 10.33 
C: Healthy matched 7.90*** 3.04** 7.29 
     
Hostility 
A: HIV positive - - 7.74 
B: HIV negative 1.81 - 5.94 
C: Healthy matched 2.77* 0.96 4.98 
     
Phobia 
A: HIV positive - - 7.77 
B: HIV negative 3.07** - 4.69 
C: Healthy matched 4.66*** 1.58 3.11 
     
Paranoid ideation 
A: HIV positive - - 11.72 
B: HIV negative 2.43 - 9.28 
C: Healthy matched 4.68*** 2.24 7.04 
     
Psychoticism 
A: HIV positive - - 15.56 
B: HIV negative 4.84** - 10.71 
C: Healthy matched 10.60*** 5.76*** 4.95 
     
Global Severity Index (GSI) 
A: HIV positive - - 1.62 
B: HIV negative 0.49** - 1.13 
C: Healthy matched 0.82** 0.32* 0.81 
     
Positive Symptom Total (PST) 
A: HIV positive - - 58.09 
B: HIV negative 11.40** - 46.69 
C: Healthy matched 16.51*** 5.12 41.58 
     
Positive Symptom Distress Index (PSDI) 
A: HIV positive - - 2.42 
B: HIV negative 0.33** - 2.08 
C: Healthy matched 0.71*** 0.38** 1.71 
*P < 0.05; **P < 0.01; ***P < 0.001 
 
Figure 1 by T standard score for all subscales of 
SCL-90-R is the best method to demonstrate the 
difference and order of mental disorder symptoms, 
and distribution of psychopathological profile of 
the 3 groups in this study.  
Discussion 
This research aimed to compare  
psychopathological dimensions in substance 
abusers with and without HIV/AIDS and their 
matched group. Finding a clear discrimination 
between and a sample of mental disorder 
symptoms in these groups is an important step in 
promotion of medical outcomes and prognosis of 
multiple chronic, mental, and medical diseases 
(addiction with HIV/AIDS). 
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Figure 1. Comparison of distribution of psychopathological profile of the 3 groups 
GSI: Global severity index; PST: Positive symptom total; PSDI: Positive symptom distress index 
 
Data showed that the population of substance 
abusers with HIV/AIDS report significantly higher 
rates of drug injection history (P = 0.041) and 
imprisonment (P < 0.012) compared to substance 
abusers without this infection. Findings have 
shown sharing contaminated needles and syringes 
is the major risk factor in HIV transmission and 
other blood borne infections.10,33 The results of this 
project and the findings of the study by Hammett 
uncovered that group imprisonment of substance 
abusers leads to a raise in HIV/AIDS infection 
compared to other routes. Nevertheless, different 
studies proved that imprisonment increases HIV 
infection rates via factors such as social support 
cessation, multiple sex partners, or risky sexual 
behaviors.34-36 These findings indicate that longer 
imprisonment in congregate and crowded 
settings, for instance in prisons, plus continuous 
injection of drugs can make the HIV infection 
more prevalent. Therefore, watchful follow-up 
and performance such as mandatory programs to 
prevent transmission of HIV/AIDS, includes: 
creating more awareness of homosexual behavior 
and sharing contaminated syringes in prisons, 
also damage-reduction interventions in DICs and 
self-proclaimed addicts, and distributing new 
syringes and collecting used ones.  
Findings of this study indicate that substance 
abusers with HIV/AIDS show significantly more 
frequency of mental disorders based on GSI in 
SCL-90-R test (88.4%) compared to substance 
abusers without HIV/AIDS (75.5%), and the 
healthy matched group (53.3%) (Table 2). 
Moreover, the majority of studies have claimed a 
close relationship between mental comorbidities 
and substance use disorders in HIV-infected 
individuals.5,6,8,10,12,17,30 Similarly, some studies have 
demonstrated that individuals with this triple 
comorbidity (mental disorder, substance abuse, 
and HIV infection) are more likely to exhibit risky 
behaviors and have an active role in fueling the 
HIV epidemic when not under therapy.37 
Results of the present effort clarified that 
substance abusers with HIV/AIDS, in all 
psychopathological dimensions, have 
significantly more symptoms compared with their 
healthy matched group (P < 0.001). In addition, 
substance abusers without HIV/AIDS show 
higher levels of symptoms (P < 0.05) in 
comorbidity dimensions of somatization,  
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interpersonal sensitivity, depression, anxiety, 
phobia, and psychoticism, GSI, PST, and PSDI. 
However, there was no significant difference 
between them in paranoid ideation and hostility 
(Table 4). These findings suggest the existence of 
important qualitative differences in 
psychopathological dimensions between these 
groups. On the other hand, multiplicity of 
significant differences among substance abusers 
with and without HIV/AIDS support the idea 
that HIV infection is not related to any special 
symptomatology. Moreover, Koutsilieri et al. have 
mentioned the development of a wide continuum 
of mental illnesses in HIV-infected substance 
abusers.37 However, we may interpret increased 
levels of comorbidity symptoms in substance 
abusers with HIV/AIDS compared to other 
groups of this study as below: 
a) Effective psychopathological factors in 
HIV/AIDS: HIV-infected individuals may 
develop some mental disorders before HIV 
infection which in turn can predispose 
individuals to HIV. Furthermore, Baillargeon et 
al. showed that major depression, dysthymia, 
bipolar disorder, schizophrenia, schizoaffective 
disorder, and non-schizophrenic psychotic 
disorder, which can be placed among chronic 
mental disorders, are more prevalent in patients 
with HIV.7 Meade et al., also found that recent 
manic episode, lower psychiatric symptom 
severity, and greater drug usage are predictors of 
HIV infection in patients with multiple bipolar 
and drug use disorders.38 In addition, according 
to findings of Atkinson et al. those with HIV 
infection reported more depression in their 
lifetime, the onset of which was before HIV 
infection in one third of the cases, in comparison 
to those without HIV. Furthermore, HIV-infected 
group, in comparison to the non-infected group, 
showed more substance use in their lifetime. 
Finally, Koutsilieri et al. postulated that substance 
abuse accelerates HIV encephalopathy 
progression. These substances activate 
mesocortical/mesolimbic dopaminergic pathways 
which in turn can lead to psychosis that is difficult 
to differentiate from schizophrenia. 
b) The outcome of psychopathology 
resulting from HIV/AIDS: As soon as the first 
positive test and the first symptoms of 
HIV/AIDS are manifested, the mental profile of 
the patient will shift to maladjustment. Denial 
and reluctant behaviors of friends, spouse, and 
family members cause acute depressive 
reactions. Moreover, the feeling of an epidemic 
factor growing in their body makes HIV patients 
feel rejected. Due to prejudgments and concerns 
about infection, these individuals are 
discriminated against in matters of their house, 
job, health care, and public support. Illogical fear 
and negative reaction of society is among the 
problems the patients, their families, and 
supportive groups still face.21 Results of previous 
studies and the present survey have found a 
considerable range of psychopathological 
dimensions in these patients including mood and 
anxiety disorders, PTSD, psychosis, suicidal 
thinking, and simultaneity of several  
mental disorders especially substance use 
disorders.3-8,12,31  
Results of the present study should be 
generalized with regard to its limitations. In this 
project, self-report method was used to evaluate 
psychopathological dimensions. Despite its 
sensitivity and good feature of mental disorder 
diagnosis, SCL-90-R cannot help us in 
descriptive and navigating researches to discover 
and compare the prevalence of mental disorders 
of different groups based on DSM-IV-TR.26 
Furthermore, SCL-90-R has not been extensively 
validated in a population with HIV/AIDS. 
Therefore, it is suggested that structured 
diagnosis interviews be used instead of 
screening diagnosis tools. The association 
between HIV/AIDS infection and manifestation 
of mental disorder symptoms can be bilateral; 
thus, the results of this study with a cross-
sectional design are not adequate. We should 
consider that conducting a study in a specific 
area cannot be indicative of the behaviors in all 
individuals with and without HIV/AIDS. Thus, 
it is proposed that future studies be carried out 
with respect to multi-center sampling and the 
dimensions of personality disorders. Here, the 
point to note is that simultaneous medical  
and mental disorders and substance use make it 
difficult to care for these patients. Thus, 
resolving these limitations is proposed for future 
efforts which should insist on the necessity  
of designing a model with the most effective 
medical services, and social and psychological 
work so these patients obtain a normal status  
of health.  
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Conclusion 
Overall, it can be stated that symptoms of mental 
disorders in substance abusers with HIV/AIDS is 
significantly more than substance abusers without 
it, and less than the matched group in all 
dimensions. Comorbidity of substance abuse and 
HIV diagnosis accentuates mental disorder 
symptoms. In addition, not preventing and 
performing appropriate psychological 
interventions following substance abuse and HIV 
infection leads to widespread establishment of 
mental disorder symptoms.   
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  ﺑﻪ ﻛﻨﻨﺪﮔﺎن ﻣﻮاد واﺟﺪ و ﻓﺎﻗﺪ اﺑﺘﻼ  ﻣﺼﺮف رواﻧﻲ در ﺳﻮء ﺷﻨﺎﺳﻲ اﺑﻌﺎد آﺳﻴﺐ
  و ﻫﻤﺘﺎﻳﺎن ﺳﺎﻟﻢ SDIA/VIH
  
  3، دﻛﺘﺮ ﺳﻴﺪ ﻣﻮﺳﻲ ﻛﺎﻓﻲ2، دﻛﺘﺮ ﺳﻨﺒﻞ ﻃﺎرﻣﻴﺎن1ﺳﺠﺎد رﺿﺎﻳﻲ
  
  
  ﭼﻜﻴﺪه
ﺗﻮاﻧﺪ  ﻣﻌﺮض ﺧﻄﺮ ﻣﻲ ﻫﺎي در ﮔﺮوهدﻳﮕﺮ  و SDIA/VIH ﺑﻪ ﺑﻴﻤﺎران ﻣﺒﺘﻼ ﻣﺼﺮف ﻣﻮاد در ﻢ اﺧﺘﻼﻻت رواﻧﻲ و ﺳﻮءﻳﻋﻼ ﺗﻮﺟﻬﻲ ﺑﻪ ﺑﻲ :ﻣﻘﺪﻣﻪ
ﻛﻨﻨﺪﮔﺎن   ﻣﺼﺮف ﺷﻨﺎﺳﻲ رواﻧﻲ در ﺳﻮء اﺑﻌﺎد آﺳﻴﺐ ﻪﻣﻘﺎﻳﺴ ﺑﺮرﺳﻲ و ،ﻫﺪف ﭘﮋوﻫﺶ ﺣﺎﺿﺮ. ﺑﺎر آورد ﮔﺴﺘﺮش آﻟﻮدﮔﻲ ﺑﻪ ﻧﺎﭘﺬﻳﺮي در ﻫﺎي ﺟﺒﺮان آﺳﻴﺐ
  .ﻫﺎ ﺑﻮد ﻫﻤﺘﺎﻳﺎن ﺳﺎﻟﻢ آن و SDIA/VIHﺑﻪ  ﻓﺎﻗﺪ اﺑﺘﻼ و ﻣﻮاد واﺟﺪ
ﻫﺎي  ﻛﻠﻴﻨﻴﻚ در ﻛﻪ VIH ﻛﻨﻨﺪه ﻣﻮاد ﻓﺎﻗﺪ ﻣﺼﺮف ﺳﻮء 94، VIH ﺑﻪ ﻣﻮاد ﻣﺒﺘﻼ هﻛﻨﻨﺪ ﻣﺼﺮف ﺳﻮء 34از ﺗﺤﻠﻴﻠﻲ  -ﭘﮋوﻫﺶ ﻣﻘﻄﻌﻲ در ﻳﻚ :ﻫﺎ روش
 54ﺑﻮدﻧﺪ و ( TMMﻳﺎ  tnemtaert ecnanetniam enodahteM) ﻣﺘﺎدون ﺪارﻧﺪه ﺑﺎﻬﭘﻮﺷﺶ درﻣﺎن ﻧﮕ  ﺗﺮك اﻋﺘﻴﺎد ﺗﺤﺖ ﻫﺎي رﻓﺘﺎري و ﻣﺸﺎوره ﺑﻴﻤﺎري
  ﮔﺮوه از ﻧﻈﺮ ﻣﺘﻐﻴﺮﻫﺎي ﻣﺨﺪوش ﺗﻤﺎم اﻋﻀﺎي اﻳﻦ ﺳﻪ. ﻋﻤﻞ آﻣﺪ  ﮔﻴﺮي ﺑﻪ دﺳﺘﺮس، ﭘﻴﺎﭘﻲ و ﻫﺪﻓﻤﻨﺪ ﻧﻤﻮﻧﻪ درﮔﻴﺮي  ﺷﻴﻮه ﻧﻤﻮﻧﻪ  ﺗﺮﺗﻴﺐ ﺑﻪ ﻓﺮد ﻋﺎدي ﺑﻪ
ﻣﻮرد ( R-09-LCSﻳﺎ  desiveR- 09-tsilkcehc motpmys) رواﻧﻲ  ﻫﺎي اﺧﺘﻼﻻت ﺷﺪه ﻧﺸﺎﻧﻪ ﻧﻈﺮ ﻟﻴﺴﺖ ﺗﺠﺪﻳﺪ ﺷﺪه و از ﻃﺮﻳﻖ ﭼﻚ ﻛﻨﻨﺪه ﻫﻤﺘﺎ
  .ﮔﺮﻓﺘﻨﺪ ارزﻳﺎﺑﻲ ﻗﺮار
 ﻫﺎي ﻣﺜﺒﺖ ، ﺷﺎﺧﺺ ﻧﺎراﺣﺘﻲ ﻧﺸﺎﻧﻪ(ISG ﺎﻳ xedni ytireves labolG) ﻲﻣﺮﺿ يﻫﺎ ﻧﺸﺎﻧﻪ ﻲﮔﺮوه از ﻧﻈﺮ ﺷﺎﺧﺺ ﺷﺪت ﻛﻠﺳﻪ  ﻳﻦﺑﻴﻦ ا :ﻫﺎ ﻳﺎﻓﺘﻪ
داري وﺟﻮد  ﺗﻔﺎوت ﻣﻌﻨﻲ( TSPﻳﺎ  latot motpmys evitisoP) ﻫﺎي ﻣﺜﺒﺖ و ﻣﺠﻤﻮع ﻧﺸﺎﻧﻪ( IDSPﻳﺎ  xedni ssertsid motpmys evitisoP)
 VIH ﺑﻪ ﻣﻮاد ﻣﺒﺘﻼ هﻣﺼﺮف ﻛﻨﻨﺪ ﻫﺎي ﺳﻮء داد ﻛﻪ ﻧﻤﻮﻧﻪ  ﺷﻨﺎﺳﻲ رواﻧﻲ ﻧﺸﺎن ﻫﺎ از ﻧﻈﺮ اﺑﻌﺎد آﺳﻴﺐ دوي ﮔﺮوهﻣﻘﺎﻳﺴﻪ دو ﺑﻪ  (.P < 0/100)ﺷﺖ دا
 و ﻣﺮﺿﻲ رواﺑﻂ ﻣﺘﻘﺎﺑﻞ، اﻓﺴﺮدﮔﻲ، اﺿﻄﺮاب، ﺗﺮس و در اﺑﻌﺎد ﺷﻜﺎﻳﺎت ﺟﺴﻤﻲ، ﺣﺴﺎﺳﻴﺖ در (P < 0/050) ﺑﻪ اﻓﺮاد ﺳﺎﻟﻢ ﻫﻤﻪ اﺑﻌﺎد ﻧﺴﺒﺖ ﻫﻤﻮاره در
اﻣﺎ اﻳﻦ ﺗﻔﺎوت در اﺑﻌﺎد اﻓﻜﺎر ، ﺑﻮدﻧﺪرواﻧﻲ ﺑﻴﺸﺘﺮي  ﻞ آﺳﻴﺐﻤﻣﺘﺤ (P < 0/050) VIH ﻓﺎﻗﺪ ﻛﻨﻨﺪﮔﺎن ﻣﻮاد  ﻣﺼﺮف ﺑﻪ ﺳﻮء ﺧﻮﻳﻲ ﻧﺴﺒﺖ ﭘﺮﻳﺶ روان
 ﻧﻴﺰ VIH ﻓﺎﻗﺪ ﻣﻮاد هﻛﻨﻨﺪ  ﻣﺼﺮف دوي اﻓﺮاد ﺳﺎﻟﻢ و ﺳﻮء  ﻣﻘﺎﻳﺴﻪ دو ﺑﻪ. ﻇﺎﻫﺮ ﻧﺸﺪ دار ﻫﺎ ﻣﻌﻨﻲ ﻋﻤﻠﻲ ﺑﻴﻦ آن - ﭘﺎراﻧﻮﺋﻴﺪي، ﺧﺼﻮﻣﺖ و وﺳﻮاس ﻓﻜﺮي
داري ﺑﺎ  اﻣﺎ از ﻧﻈﺮ ﺳﺎﻳﺮ اﺑﻌﺎد ﺗﻔﺎوت ﻣﻌﻨﻲ، (P < 0/050) ﻛﻨﻨﺪﮔﺎن ﻣﻮاد ﺑﻮد ﻣﺼﺮف ﺧﻮﻳﻲ در ﺳﻮء ﭘﺮﻳﺶ اﻓﺴﺮدﮔﻲ و روان ﻧﺸﺎﻧﮕﺮ ﺗﺠﺮﺑﻪ ﺳﻄﻮح ﺑﺎﻻﺗﺮ
  .ﻳﻜﺪﻳﮕﺮ ﻧﺪاﺷﺘﻨﺪ
ﻋﺪم ﭘﻴﺸﮕﻴﺮي و  ،ﺑﺮ آن اﻓﺰون. ﮔﺮدد ﻢ اﺧﺘﻼﻻت رواﻧﻲ ﻣﻲﻳﻋﻼ زدن ﺑﻪ ﻣﻮﺟﺐ داﻣﻦ VIH ﺗﺸﺨﻴﺺ ﻣﺼﺮف ﻣﻮاد و ﻫﻤﺒﻮدي ﺳﻮء :ﮔﻴﺮي ﻧﺘﻴﺠﻪ
ﻢ اﺧﺘﻼﻻت رواﻧﻲ ﻳﺑﻪ اﺳﺘﻘﺮار ﮔﺴﺘﺮده ﻋﻼ ﻣﻨﺠﺮ VIHﺑﻪ  و اﺑﺘﻼ ﻣﺼﺮف ﻣﻮاد ﭘﺰﺷﻜﻲ ﻣﻨﺎﺳﺐ ﭘﺲ از ﺳﻮء ﺷﻨﺎﺧﺘﻲ و روان ﺳﺎزي ﻣﺪاﺧﻼت روان ﭘﻴﺎده
  .آﻳﻨﺪه ﻣﻮرد ﺑﺤﺚ ﻗﺮار ﮔﺮﻓﺘﻪ اﺳﺖ  ﻫﺎي ﮔﻴﺮي ﺑﺮاي ﭘﮋوﻫﺶ ﻫﺎي ﺿﻤﻨﻲ اﻳﻦ ﻧﺘﺎﻳﺞ ﺑﺎ ذﻛﺮ ﺟﻬﺖ ﺑﺮﺧﻲ دﻻﻟﺖ. ﺧﻮاﻫﺪ ﺷﺪ
  R-09-LCSﺷﻨﺎﺳﻲ رواﻧﻲ،  ، آﺳﻴﺐSDIA/VIHﻣﺼﺮف ﻣﻮاد،  ﺳﻮء :ﻛﻠﻴﺪيواژﮔﺎن 
 ﺑﻪ ﻛﻨﻨﺪﮔﺎن ﻣﻮاد واﺟﺪ و ﻓﺎﻗﺪ اﺑﺘﻼ  ﻣﺼﺮف ﺷﻨﺎﺳﻲ رواﻧﻲ در ﺳﻮء اﺑﻌﺎد آﺳﻴﺐ .ﺳﻴﺪ ﻣﻮﺳﻲ ﻛﺎﻓﻲﺳﻨﺒﻞ،  ﺳﺠﺎد، ﻃﺎرﻣﻴﺎنرﺿﺎﻳﻲ  :ارﺟﺎع
  .511- 521: (3-4) 5؛ 2931 ﻣﺠﻠﻪ اﻋﺘﻴﺎد و ﺳﻼﻣﺖ .و ﻫﻤﺘﺎﻳﺎن ﺳﺎﻟﻢ SDIA/VIH
19/11/4: ﺗﺎرﻳﺦ ﭘﺬﻳﺮش  19/7/82: ﺗﺎرﻳﺦ درﻳﺎﻓﺖ
  
 ﻣﻘﺎﻟﻪ ﭘﮋوﻫﺸﻲ
